Answers are grounded in this paper and cite their sources.
Immune checkpoint inhibitors (ICIs) have substantially advanced the treatment of patients with malignant melanoma. However, improving therapeutic efficacy requires identifying drug combinations that elicit durable responses without inducing intolerable toxicity. Within that context, selinexor emerges as a possible combination option that has been shown in preclinical studies to enhance the efficacy of ICI therapy.
No takes yet. Share an insight, caveat, or question.
Gouda et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: